A5031661937- Esophageal Cancer Research and Treatment
- Gastric Cancer Management and Outcomes
- Lung Cancer Treatments and Mutations
- Esophageal and GI Pathology
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Neuropeptides and Animal Physiology
- COVID-19 and healthcare impacts
- Heart Failure Treatment and Management
- Cancer-related gene regulation
- Healthcare cost, quality, practices
- Chemotherapy-related skin toxicity
- Cancer Immunotherapy and Biomarkers
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- RNA and protein synthesis mechanisms
- Bacterial Identification and Susceptibility Testing
- Lung Cancer Diagnosis and Treatment
- interferon and immune responses
- Peptidase Inhibition and Analysis
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- Nausea and vomiting management
- PARP inhibition in cancer therapy
- Autoimmune Bullous Skin Diseases
Queen's University Belfast
2020-2023
The Northern Ireland Cancer Centre
2022-2023
Guy's Hospital
2016
Hillingdon Hospitals NHS Foundation Trust
2016
University College Hospital
2015
University College London
2015
Imperial College London
2014
Bullous pemphigoid is a blistering skin disorder with increased mortality. We tested whether strategy of starting treatment doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over oral corticosteroids.We did pragmatic, multicentre, parallel-group randomised controlled trial adults bullous (three or more blisters at two sites and linear basement membrane IgG C3). Participants were randomly assigned to (200 mg per day) prednisolone (0·5 mg/kg...
The genetic sequence variation of people from the Indian subcontinent who comprise one-quarter world's population, is not well described. We carried out whole genome sequencing 168 South Asians, along with whole-exome 147 Asians to provide deeper characterisation coding regions. identify 12,962,155 autosomal variants, including 2,946,861 new SNPs and 312,738 novel indels. This catalogue indels amongst provides first comprehensive map in this major human reveals evidence for selective...
PURPOSE There is limited evidence regarding the prognostic effects of pathologic lymph node (LN) regression after neoadjuvant chemotherapy for esophageal adenocarcinoma, and a definition LN response lacking. This study aimed to evaluate how influences survival surgery adenocarcinoma. METHODS Multicenter cohort patients with adenocarcinoma treated followed by surgical resection at five high-volume centers in United Kingdom. LNs retrieved esophagectomy were examined given score (LNRS)—LNRS 1,...
The COVID-19 pandemic has dramatically impacted gastroenterology services worldwide. As coronavirus infection rates rose, many professional bodies advised that all endoscopy, except emergency and essential procedures, be stopped immediately.1British Society of Gastroenterologyhttps://www.bsg.org.uk/covid-19-advice/endoscopy-activity-and-covid-19-bsg-and-jag-guidance/Date accessed: November 1, 2020Google Scholar,2Chiu P.W.Y. et al.Gut. 2020; 69: 991-996Crossref PubMed Scopus (243) Google...
4539 Background: The Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC) trial reported an acceptable safety profile for neoadjuvant Xelox +/- AZD8931 but limited efficacy. We utilized EAC patient samples from DEBIOC to evaluate the impact of +/-AZD8931 on biological pathways using a unique software driven solution. Methods: 24 pre-treatment FFPE biopsies and 17 matched surgical resection specimens were transcriptionally profiled Almac Diagnostics Xcel Array. Gene expression data was...
Abstract The prognostic benefit of primary tumour and lymph node (LN) downstaging after neoadjuvant chemotherapy for oesophageal adenocarcinoma (OAC) is well described. However, there no robust evidence regarding the effect pathological LN regression despite emerging a discrepancy, in some patients, between grade response regional LNs. aim this study was to investigate relationship regression, recurrence survival. Retrospective, multicentre cohort including 763 patients with OAC treated...
Abstract Background The prognostic benefits of primary tumour and lymph node (LN) downstaging after neoadjuvant chemotherapy for oesophageal adenocarcinoma are well described. Pathological regression grading (TRG) is widely used in the assessment response to has been shown have value this patient group. However, there a lack robust evidence regarding effect pathological LN despite emerging discrepancy, up 25% patients some studies, between TRG regional LNs. Although routinely documented as...
Abstract Objective The COVID-19 pandemic has placed an inexorable strain on endoscopy services worldwide, affecting the diagnosis of esophago-gastric (EG) cancer and Barrett’s esophagus (BE). As coronavirus infection rates rose many professional bodies advised that all endoscopy, except emergency essential procedures, be stopped immediately. We sought to quantify decline in EG BE diagnoses following implementation British Society Gastroenterology (BSG) guidance related psychosocial effects...
18F-fluorodeoxyglucose PET-CT may guide treatment decisions in patients with oesophageal adenocarcinoma (OAC). This study evaluated the added value of maximum standardised uptake (SUVmax) to a novel DNA-damage immune response (DDIR) assay improve pathological prediction. The diagnostic accuracy PET and prognostic significance metrics for recurrence-free survival (RFS) overall (OS) were assessed. was retrospective, single-centre OAC treated neo-adjuvant chemotherapy from 2003 2014. SUVmax...
Abstract Background The COVID-19 pandemic has placed an inexorable strain on endoscopy services worldwide, affecting the diagnosis of oesophago-gastric (OG) cancer and Barrett’s oesophagus (BO). As coronavirus infection rates rose many professional bodies advised that all endoscopy, except emergency essential procedures be stopped immediately. We sought to quantify decline in OG BO diagnoses following implementation British Society Gastroenterology (BSG) guidance related psychosocial effects...
Abstract Background Oesophageal Adenocarcinoma (OAC) incidence in the Western-world has increased markedly over 30 years. 5-year survival rates for patients remains below 20% with dismal response to neo-adjuvant or perioperative chemotherapy operable tumours. The Dual ErbB Inhibition Oesophago-gastric Cancer (DEBIOC) clinical trial assessed efficacy of combined oxaliplatin and capecitabine (Xelox) dual inhibitor AZD8931 providing additional benefit compared Xelox alone. We utilised a...